4th Quarter - Report — COHERUS BIOSCIENCES for COHERUS BIOSCIENCES, INC. (2022)

Firm

COHERUS BIOSCIENCES

Client

COHERUS BIOSCIENCES, INC.

Income

—

Expenses

$275,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug Pricing Reform Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act, ASP+8 H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act

Lobbyist	Covered position, as disclosed
BEN KENNEY	Director of Strategic Communications and Stakeholder Engagement, Centers for Medicare and Medicaid Services (2018-2021), Associate Administrator, General Services Administration (2017-2018), Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
AMANDA MAJOR	—
ALI MCBRIDE	—
DAVID SANDERS	Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007) Legislative Assistant, Representative Marsha Blackburn (2002-2004) Legislative and Press Intern, Senator Fred Thompson (2000)

Contacted: Food & Drug Administration (FDA); Executive Office of the President (EOP); Office of Management & Budget (OMB); Defense, Dept of (DOD); White House Office; Office of Science & Technology Policy (OSTP); SENATE; Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 7400 (117th), S. 2082 (117th), H.R. 5376 (117th), H.R. 2815 (117th), S. 1176 (117th), S. 1427 (117th), H.R. 3683 (117th), S. 3799 (117th), S. 1693 (117th), S. 2662 (117th), H.R. 2870 (117th), H.R. 2869 (117th), S. 3991 (117th)

Government Issues GOV

Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Drug Pricing Reform Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation

Lobbyist	Covered position, as disclosed
BEN KENNEY	CMS, HHS
AMANDA MAJOR	—
ALI MCBRIDE	—
DAVID SANDERS	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; White House Office; Office of Management & Budget (OMB); Food & Drug Administration (FDA); Executive Office of the President (EOP)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.